# HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06849492/  
OnCo record `nct06849492` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab, nab-paclitaxel, sacituzumab tirumotecan and lenvatinib in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06849492 by Fudan University, with a registry enrolment figure of 120 participants, started 2025-04-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Camrelizumab; Nab-paclitaxel; SKB264; Lenvatinib. Conditions listed: Advanced Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histopathologically confirmed recurrent metastatic triple-negative invasive breast cancer (HER2-negative: IHC 0/1+ or IHC 2+ with negative ISH; ER-negative: IHC \<1%, PR-negative: IHC \<1%)；". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: SHIFT-001
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06849492
- Phase: 2
- Setting: An Open, Multicenter Study on the Treatment of Recurrent and Metastatic Triple-negative Breast Cancer Guided by Cell Surface Protein Typing (HIM) in Triple-negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06849492: https://clinicaltrials.gov/study/NCT06849492

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06849492.json